NCT02312102 2026-01-16
Velcade and Lenalidomide in Patients With Relapsed AML and MDS After Allogeneic Stem Cell Transplantation
Massachusetts General Hospital
Phase 1 Completed
Clinical Trials
6 trialsNCT00789256 2018-10-24
Low Dose Melphalan and Bortezomib for AML and High-Risk MDS
Dartmouth-Hitchcock Medical Center
Phase NA Completed
NCT01891968 2018-04-23
Bortezomib for Low or Intermediate-1 Myelodysplastic Syndrome (MDS) With p65 Activation
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00624936 2017-08-22
Azacytidine and Bortezomib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
NCT01323920 2017-05-30
Bortezomib-based GVHD Prophylaxis After Allogeneic Transplant for Patients Without Matched Related Donors
Dana-Farber Cancer Institute
Phase 2 Completed
NCT01075425 2016-04-15
Belinostat and Bortezomib in Treating Patients With Relapsed or Refractory Acute Leukemia or Myelodysplastic Syndrome
Virginia Commonwealth University
Phase 1 Completed